Cutting Social Isolation, Loneliness May Lower Mortality in People With Obesity

24 Jan 2024
www.drugs.com
Clinical Result
WEDNESDAY, Jan. 24, 2024 -- Improving social isolation and loneliness may attenuate excess obesity-related mortality risk, according to a study published online Jan. 22 in JAMA Network Open.
Jian Zhou, M.D., from the Tulane University School of Public Health and Tropical Medicine in New Orleans, and colleagues investigated whether improvement of social isolation or loneliness is associated with a lower obesity-related excess risk for mortality. The analysis included data from 398,972 participants in the U.K. Biobank with follow-up from March 2006 to November 2021.
The researchers found that compared with participants with obesity and an index of ≥2 for social isolation, risk for all-cause mortality was lower for participants with obesity and a social isolation index of 1 and 0. A similar trend was seen when comparing participants with obesity and a loneliness index of 1 and 0 with those with an index of 2 for loneliness. Risk for all-cause mortality decreased as the index of social isolation and loneliness went from highest to lowest in people with obesity versus people without obesity (hazard ratios decreased by 36 and 9 percent, respectively). Social isolation was ranked higher than loneliness, depression, anxiety, and lifestyle-related risk factors (e.g., alcohol, physical activity, and healthy diet) for estimating the risks for all-cause, cancer-related, and cardiovascular disease-related mortality.
"These findings support the improvement of social isolation and loneliness in people with obesity to decrease obesity-related excess risk of mortality," the authors write.
Abstract/Full Text
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.